Gilgamesh Withdraws Patent Fight Against Enveric After $1.2 Billion AbbVie Deal, CEO Says Key Drug Claims Now Uncontested [Benzinga]
Wednesday, February 25, 2026 1 min read
Key Takeaway: Enveric Biosciences announced that Gilgamesh Pharmaceuticals has withdrawn its Post-Grant Review petition against Enveric's U.S. Patent No. 12,138,276. This decision leaves Enveric's patent claims uncontested, following a recent $1.2 billion deal with AbbVie. The withdrawal marks a significant milestone for Enveric in securing its intellectual property.
Price reaction · baseline $2.2 (2026-02-24 close) · hit pre-market · 2 other ENVB headline(s) in the window, move may be shared
day 0 close · peak
+9.1%
day 1
+5.5%
day 3
+2.3%
Market Sentiment Analysis
POSITIVE FACTORS
Gilgamesh has withdrawn its patent challenge against Enveric.
Enveric's key drug claims are now uncontested.
This withdrawal follows a significant deal with AbbVie.
Full Press Release Details
Enveric Biosciences Inc. (NASDAQ:ENVB) on Wednesday said that the previously announced Post-Grant Review (PGR) petition filed by Gilgamesh Pharmaceuticals Inc. against Enveric’s issued U.S. Patent No. 12,138,276 (the ‘276 patent) has been withdrawn. The action follows Enveric’s filing of a Request for Discretionary Denial of the petition. As a result, there are no remaining challenges currently pending against Enveric’s patent.
Full Article >>
Frequently Asked Questions
What patent challenge was withdrawn?
Gilgamesh Pharmaceuticals withdrew its Post-Grant Review petition against Enveric's patent.
What is U.S. Patent No. 12,138,276?
It is the patent issued to Enveric that was previously challenged by Gilgamesh.
What does this withdrawal mean for Enveric?
It means Enveric's key drug claims are now uncontested.
What recent deal is mentioned in the article?
Enveric recently secured a $1.2 billion deal with AbbVie.